Comparative Pharmacology
Head-to-head clinical analysis: NALMEFENE HYDROCHLORIDE versus NALOXONE HYDROCHLORIDE AUTOINJECTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALMEFENE HYDROCHLORIDE versus NALOXONE HYDROCHLORIDE AUTOINJECTOR.
NALMEFENE HYDROCHLORIDE vs NALOXONE HYDROCHLORIDE (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nalmefene is an opioid receptor antagonist with high affinity for mu, kappa, and delta receptors, and partial agonist activity at kappa receptors.
Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid-induced respiratory depression and analgesia.
18 mcg intranasally once, repeated after 2-3 minutes if needed; maximum 2 doses (36 mcg) per episode. Alternatively, 0.5 mg subcutaneously or intramuscularly once, repeated after 2-3 minutes if needed; maximum 1.5 mg per episode.
Initial: 0.4 mg or 2 mg intramuscularly (IM) or subcutaneously (SC); may repeat every 2-3 minutes as needed. For autoinjector: 2 mg single dose, administer IM or SC into anterolateral thigh; may repeat every 2-3 minutes with a new device if no response. Max total dose: 10 mg.
None Documented
None Documented
Terminal elimination half-life: ~10.8 hours (range 8–13 hours); clinically supports twice-daily dosing or use in alcohol use disorder
Terminal elimination half-life approximately 1 to 1.5 hours in adults. In neonates, half-life is prolonged (about 3 hours). Clinical context: due to short half-life, repeated doses or continuous infusion may be needed for opioid overdose with long-acting opioids.
Primarily renal (approximately 50% unchanged drug); biliary/fecal excretion accounts for ~20%
Primarily hepatic metabolism (glucuronidation) followed by renal excretion of metabolites. Less than 1% excreted unchanged in urine. Fecal excretion minimal (<5%).
Category C
Category A/B
Opioid Antagonist
Opioid Antagonist